Clonal Hematopoiesis and Plasma Cell Disorders: Coincidence or not?
Main Article Content
Abstract
'
Article Details
How to Cite
DEBUREAUX, Pierre-Edouard et al.
Clonal Hematopoiesis and Plasma Cell Disorders: Coincidence or not?.
Medical Research Archives, [S.l.], v. 13, n. 7, july 2025.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/6519>. Date accessed: 05 dec. 2025.
doi: https://doi.org/10.18103/mra.v13i7.6519.
Section
Editorial
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med. 2006; 354(13):1362-1369. doi:10.1056/NEJMoa054494
2. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377( 2):111-121. doi:10.1056/NEJMoa1701719
3. Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-1485. doi:10.1182/blood-2018-04-839480
4. Da Vià MC, Lionetti M, Marella A, et al. MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. Blood Adv. 2022;6(21):5702-5706.
doi:10.1182/bloodadvances.2021006498
5. Boddicker NJ, Parikh SA, Norman AD, et al. Relationship among three common hematological premalignant conditions. Leukemia. 2023;37(8):1719-1722. doi:10.1038/s41375-023-01914-z
6. Mouhieddine TH, Sperling AS, Redd R, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11(1):2996.
doi:10.1038/s41467-020-16805-5
7. Tahri S, Mouhieddine TH, Redd R, et al. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. Published online December 2, 2021. doi:10.1182/bloodadvances.2 021004926
8. Hecker JS, Hartmann L, Rivière J, et al. CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood. 2021;138(18):1727-1732. doi:10.1182/blood.2020010163
9. Busque L, Sun M, Buscarlet M, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2020;4(11):2430-2438. doi:10.1182/bl oodadvances.2019000770
10. Zhao LP, Boy M, Azoulay C, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;35(9):2720-2724. doi:10.1038/s41375-021-01152-1
11. Bick AG, Weinstock JS, Nandakumar SK, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586(7831):763-768. doi:10.1038/s41586-020-2819-2
12. Cook EK, Izukawa T, Young S, et al. Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Adv. 2019;3(16): 2482-2486. doi:10.1182/bloodadvances.2018024729
13. Han W, Matissek SJ, Jackson DA, Sklavanitis B, Elsawa SF. Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. Oncotarget. 2019;10(36):3400-3407. doi:10.18632/o ncotarget.26946
14. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component. Mayo Clin Proc. 2009;84(2):114-122. doi:10.4065/84.2.114
15. Debureaux PE, Poulain S, Harel S, et al. Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort. Blood. 2025;145(4):450-454. doi:10.1182/b lood.2024025738
16. Debureaux PE, Forgeard N, Elessa D, et al. Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study. Haematologica. Published online 2020. doi:10.3324/haematol.2023.283141
17. Forgeard N, Baron M, Caron J, et al. Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. Haematologica. 2022;107(11): 2720-2724. doi:10.3324/haematol.2022.281053
18. García-Sanz R, Dogliotti I, Zaccaria GM, et al. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol. 2021;192(5):843-852. doi:10.1111/bjh.17028
19. Arends CM, Galan-Sousa J, Hoyer K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018; 32(9):1908-1919. doi:10.1038/s41375-018-0047-7
20. Lionetti M, Scopetti M, Matera A, et al. Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes. Blood. Published online March 20, 2025:blood.2024026236. doi:10.1182/b lood.2024026236
2. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377( 2):111-121. doi:10.1056/NEJMoa1701719
3. Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478-1485. doi:10.1182/blood-2018-04-839480
4. Da Vià MC, Lionetti M, Marella A, et al. MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. Blood Adv. 2022;6(21):5702-5706.
doi:10.1182/bloodadvances.2021006498
5. Boddicker NJ, Parikh SA, Norman AD, et al. Relationship among three common hematological premalignant conditions. Leukemia. 2023;37(8):1719-1722. doi:10.1038/s41375-023-01914-z
6. Mouhieddine TH, Sperling AS, Redd R, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11(1):2996.
doi:10.1038/s41467-020-16805-5
7. Tahri S, Mouhieddine TH, Redd R, et al. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. Published online December 2, 2021. doi:10.1182/bloodadvances.2 021004926
8. Hecker JS, Hartmann L, Rivière J, et al. CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood. 2021;138(18):1727-1732. doi:10.1182/blood.2020010163
9. Busque L, Sun M, Buscarlet M, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2020;4(11):2430-2438. doi:10.1182/bl oodadvances.2019000770
10. Zhao LP, Boy M, Azoulay C, et al. Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;35(9):2720-2724. doi:10.1038/s41375-021-01152-1
11. Bick AG, Weinstock JS, Nandakumar SK, et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature. 2020;586(7831):763-768. doi:10.1038/s41586-020-2819-2
12. Cook EK, Izukawa T, Young S, et al. Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Adv. 2019;3(16): 2482-2486. doi:10.1182/bloodadvances.2018024729
13. Han W, Matissek SJ, Jackson DA, Sklavanitis B, Elsawa SF. Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. Oncotarget. 2019;10(36):3400-3407. doi:10.18632/o ncotarget.26946
14. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component. Mayo Clin Proc. 2009;84(2):114-122. doi:10.4065/84.2.114
15. Debureaux PE, Poulain S, Harel S, et al. Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort. Blood. 2025;145(4):450-454. doi:10.1182/b lood.2024025738
16. Debureaux PE, Forgeard N, Elessa D, et al. Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study. Haematologica. Published online 2020. doi:10.3324/haematol.2023.283141
17. Forgeard N, Baron M, Caron J, et al. Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation. Haematologica. 2022;107(11): 2720-2724. doi:10.3324/haematol.2022.281053
18. García-Sanz R, Dogliotti I, Zaccaria GM, et al. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol. 2021;192(5):843-852. doi:10.1111/bjh.17028
19. Arends CM, Galan-Sousa J, Hoyer K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018; 32(9):1908-1919. doi:10.1038/s41375-018-0047-7
20. Lionetti M, Scopetti M, Matera A, et al. Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes. Blood. Published online March 20, 2025:blood.2024026236. doi:10.1182/b lood.2024026236